Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Phase 1 Trial of Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

NCT04051047 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT04051047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04051047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Phase 1 Trial of Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 1
Overall status
Withdrawn
Start date
November 30, 2019
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, glial tumor of brain, glioma